Literature DB >> 19264868

Excessive ovarian production of nerve growth factor facilitates development of cystic ovarian morphology in mice and is a feature of polycystic ovarian syndrome in humans.

Gregory A Dissen1, Cecilia Garcia-Rudaz, Alfonso Paredes, Christine Mayer, Artur Mayerhofer, Sergio R Ojeda.   

Abstract

Although ovarian nerve growth factor (NGF) facilitates follicular development and ovulation, an excess of the neurotrophin in the rodent ovary reduces ovulatory capacity and causes development of precystic follicles. Here we show that ovarian NGF production is enhanced in patients with polycystic ovarian syndrome (PCOS) and that transgenically driven overproduction of NGF targeted to the ovary results in cystic morphology, when accompanied by elevated LH levels. NGF levels are increased in the follicular fluid from PCOS ovaries and in the culture medium of granulosa cells from PCOS patients, as compared with non-PCOS patients. Ovaries from transgenic mice carrying the NGF gene targeted to thecal-interstitial cells by the 17alpha-hydroxylase gene promoter produce more NGF than wild-type (WT) ovaries and are hyperinnervated by sympathetic nerves. Antral follicle growth is arrested resulting in accumulation of intermediate size follicles, many of which are apoptotic. Peripubertal transgenic mice respond to a gonadotropin challenge with a greater increase in plasma 17-hydroxyprogesterone, estradiol, and testosterone levels than WT controls. Transgenic mice also exhibit a reduced ovulatory response, delayed puberty, and reduced fertility, as assessed by a prolonged interval between litters, and a reduced number of pups per litter. Sustained, but mild, elevation of plasma LH levels results in a heightened incidence of ovarian follicular cysts in transgenic mice as compared with WT controls. These results suggest that overproduction of ovarian NGF is a component of polycystic ovarian morphology in both humans and rodents and that a persistent elevation in plasma LH levels is required for the morphological abnormalities to appear.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19264868      PMCID: PMC2689806          DOI: 10.1210/en.2008-1575

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  44 in total

1.  Nerve growth factor production in sheep antral follicles.

Authors:  M Mattioli; B Barboni; L Gioia; P Lucidi
Journal:  Domest Anim Endocrinol       Date:  1999-11       Impact factor: 2.290

2.  Direct effects of nerve growth factor on thecal cells from antral ovarian follicles.

Authors:  G A Dissen; J A Parrott; M K Skinner; D F Hill; M E Costa; S R Ojeda
Journal:  Endocrinology       Date:  2000-12       Impact factor: 4.736

3.  Muscarinic receptors in human luteinized granulosa cells: activation blocks gap junctions and induces the transcription factor early growth response factor-1.

Authors:  Stephanie Fritz; Lars Kunz; Nicola Dimitrijevic; Robert Grünert; Christoph Heiss; Artur Mayerhofer
Journal:  J Clin Endocrinol Metab       Date:  2002-03       Impact factor: 5.958

4.  Effects of electro-acupuncture on nerve growth factor and ovarian morphology in rats with experimentally induced polycystic ovaries.

Authors:  E Stener-Victorin; T Lundeberg; U Waldenström; L Manni; L Aloe; S Gunnarsson; P O Janson
Journal:  Biol Reprod       Date:  2000-11       Impact factor: 4.285

5.  D1-Receptor, DARPP-32, and PP-1 in the primate corpus luteum and luteinized granulosa cells: evidence for phosphorylation of DARPP-32 by dopamine and human chorionic gonadotropin.

Authors:  A Mayerhofer; S Fritz; R Grünert; S L Sanders; D M Duffy; S R Ojeda; R L Stouffer
Journal:  J Clin Endocrinol Metab       Date:  2000-12       Impact factor: 5.958

6.  Tumor necrosis factor-induced microtubule stabilization mediated by hyperphosphorylated oncoprotein 18 promotes cell death.

Authors:  K Vancompernolle; T Boonefaes; M Mann; W Fiers; J Grooten
Journal:  J Biol Chem       Date:  2000-10-27       Impact factor: 5.157

7.  Increase in nerve fibers and loss of mast cells in polycystic and postmenopausal ovaries.

Authors:  U Heider; I Pedal; K Spanel-Borowski
Journal:  Fertil Steril       Date:  2001-06       Impact factor: 7.329

8.  Intraovarian excess of nerve growth factor increases androgen secretion and disrupts estrous cyclicity in the rat.

Authors:  G A Dissen; H E Lara; V Leyton; A Paredes; D F Hill; M E Costa; A Martinez-Serrano; S R Ojeda
Journal:  Endocrinology       Date:  2000-03       Impact factor: 4.736

9.  Increased androgen response to follicle-stimulating hormone administration in women with polycystic ovary syndrome.

Authors:  Deborah S Wachs; Mickey S Coffler; Pamela J Malcom; Shunichi Shimasaki; R Jeffrey Chang
Journal:  J Clin Endocrinol Metab       Date:  2008-02-19       Impact factor: 5.958

Review 10.  Current concepts in the polycystic ovary syndrome.

Authors:  A Dunaif; A Thomas
Journal:  Annu Rev Med       Date:  2001       Impact factor: 13.739

View more
  39 in total

1.  Brown adipose tissue transplantation ameliorates polycystic ovary syndrome.

Authors:  Xiaoxue Yuan; Tao Hu; Han Zhao; Yuanyuan Huang; Rongcai Ye; Jun Lin; Chuanhai Zhang; Hanlin Zhang; Gang Wei; Huiqiao Zhou; Meng Dong; Jun Zhao; Haibin Wang; Qingsong Liu; Hyuek Jong Lee; Wanzhu Jin; Zi-Jiang Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-22       Impact factor: 11.205

Review 2.  The physiological basis of complementary and alternative medicines for polycystic ovary syndrome.

Authors:  Nazia Raja-Khan; Elisabet Stener-Victorin; XiaoKe Wu; Richard S Legro
Journal:  Am J Physiol Endocrinol Metab       Date:  2011-04-12       Impact factor: 4.310

Review 3.  Ovarian and Extra-Ovarian Mediators in the Development of Polycystic Ovary Syndrome.

Authors:  Muraly Puttabyatappa; Vasantha Padmanabhan
Journal:  J Mol Endocrinol       Date:  2018-10-16       Impact factor: 5.098

4.  Excessive ovarian production of nerve growth factor elicits granulosa cell apoptosis by setting in motion a tumor necrosis factor α/stathmin-mediated death signaling pathway.

Authors:  Cecilia Garcia-Rudaz; Mauricio Dorfman; Srinivasa Nagalla; Konstantin Svechnikov; Olle Söder; Sergio R Ojeda; Gregory A Dissen
Journal:  Reproduction       Date:  2011-06-06       Impact factor: 3.906

Review 5.  Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome.

Authors:  Daniel A Dumesic; Sharon E Oberfield; Elisabet Stener-Victorin; John C Marshall; Joop S Laven; Richard S Legro
Journal:  Endocr Rev       Date:  2015-10       Impact factor: 19.871

Review 6.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

Review 7.  The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS as Functional Ovarian Hyperandrogenism Revisited.

Authors:  Robert L Rosenfield; David A Ehrmann
Journal:  Endocr Rev       Date:  2016-07-26       Impact factor: 19.871

8.  Heart Rate Changes in Electroacupuncture Treated Polycystic Ovary in Rats.

Authors:  Mukilan Ramadoss; Gunasekaran Ramanathan; Angelie Jessica Subbiah; Chidambaranathan Natrajan
Journal:  J Clin Diagn Res       Date:  2016-03-01

9.  Nerve growth factor induces vascular endothelial growth factor expression in granulosa cells via a trkA receptor/mitogen-activated protein kinase-extracellularly regulated kinase 2-dependent pathway.

Authors:  Marcela Julio-Pieper; Patricia Lozada; Veronica Tapia; Margarita Vega; Cristián Miranda; David Vantman; Sergio R Ojeda; Carmen Romero
Journal:  J Clin Endocrinol Metab       Date:  2009-05-19       Impact factor: 5.958

10.  Androgenic Sensitivities and Ovarian Gene Expression Profiles Prior to Treatment in Japanese Eel (Anguilla japonica).

Authors:  Yung-Sen Huang; Wen-Chih Cheng; Chung-Yen Lin
Journal:  Mar Biotechnol (NY)       Date:  2021-06-30       Impact factor: 3.619

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.